Research progress in acquired cystic disease-associated renal cell carcinoma

doi:10.3969/j.issn.1674-8115.2022.05.018

Abstract

Abstract:

Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is the most common type of RCC seen in patients with end-stage renal disease and acquired cystic kidney disease, and was added to the list of RCC subtypes in the 2016 World Health Organization classification. ACD-RCC is generally believed to be indolent, however, some tumors may show local recurrence and distant metastasis. Periodic screening should be performed in dialysis patients, especially in younger patients with minor comorbidities, early detection and early intervention can improve the prognosis and quality of life. Literatures published at home and abroad mainly focused on it's clinicopathological features, there is scarce research describing the imaging appearance, prognosis and surveillance of ACD-RCC. This paper summarizes the epidemiology, etiology, pathological features, imaging manifestations, treatment, prognosis and surveillance of ACD-RCC, and aims to provide a compressive understanding of the disease for clinicians.

Key words: acquired cystic disease, renal cell carcinoma, image features, prognosis

CLC Number:

R737.11

XIANG Han, XIANG Wu, ZHANG Weiguo. Research progress in acquired cystic disease-associated renal cell carcinoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(5): 680-684.

TrendMD

References 34

1	TICKOO S K, DEPERALTA-VENTURINA M N, HARIK L R, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia[J]. Am J Surg Pathol, 2006, 30(2): 141-153.
2	PRZYBYCIN C G, HARPER H L, REYNOLDS J P, et al. Acquired cystic disease-associated renal cell carcinoma (ACD-RCC): a multiinstitutional study of 40 cases with clinical follow-up[J]. Am J Surg Pathol, 2018, 42(9): 1156-1165.
3	MOCH H, CUBILLA A L, HUMPHREY P A, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours[J]. Eur Urol, 2016, 70(1): 93-105.
4	INAMURA K. Renal cell tumors: understanding their molecular pathological epidemiology and the 2016 WHO classification[J]. Int J Mol Sci, 2017, 18(10): E2195.
5	FOSHAT M, EYZAGUIRRE E. Acquired cystic disease-associated renal cell carcinoma: review of pathogenesis, morphology, ancillary tests, and clinical features[J]. Arch Pathol Lab Med, 2017, 141(4): 600-606.
6	ISHIHARA H, YAMASHITA S, LIU Y Y, et al. Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end-stage renal disease[J]. Cancer Sci, 2020, 111(11): 4276-4287.
7	MEOLA M, SAMONI S, PETRUCCI I. Clinical scenarios in chronic kidney disease: kidneys' structural changes in end-stage renal disease[J]. Contrib Nephrol, 2016, 188: 131-143.
8	KALIL R S, LYNCH C F, ENGELS E A. Risk of cancer in retransplants compared to primary kidney transplants in the United States[J]. Clin Transplant, 2015, 29(10): 944-950.
9	TSUZUKI T, IWATA H, MURASE Y, et al. Renal tumors in end-stage renal disease: a comprehensive review[J]. Int J Urol, 2018, 25(9): 780-786.
10	SHAH A, LAL P, TOORENS E, et al. Acquired cystic kidney disease-associated renal cell in KMT2C and TSC2 genes[J]. Am J Surg Pathol, 2020, 44(11): 1479-1486.
11	FUSHIMI F, TAGUCHI K, IZUMI H, et al. Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma[J]. Virchows Arch, 2013, 463(4): 553-562.
12	HORI Y, ODA Y, KIYOSHIMA K, et al. Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis[J]. J Pathol, 2007, 212(2): 218-226.
13	TOYOKUNI S. The origin and future of oxidative stress pathology: from the recognition of carcinogenesis as an iron addiction with ferroptosis-resistance to non-thermal plasma therapy[J]. Pathol Int, 2016, 66(5): 245-259.
14	CHEN T T, ACHAN A, WONG G. Acquired cystic disease-associated renal cell carcinoma[J]. Nephrology (Carlton), 2018, 23(7): 704-705.
15	KOJIMA F, GANDHI J S, MATSUZAKI I, et al. Comprehensive clinicopathologic analyses of acquired cystic disease-associated renal cell carcinoma with focus on adverse prognostic factors and metastatic lesions[J]. Am J Surg Pathol, 2020, 44(8): 1031-1039.
16	KURODA N, TAMURA M, HAMAGUCHI N, et al. Acquired cystic disease-associated renal cell carcinoma with sarcomatoid change and rhabdoid features[J]. Ann Diagn Pathol, 2011, 15(6): 462-466.
17	SRIGLEY J R, DELAHUNT B, EBLE J N, et al. The international society of urological pathology (ISUP) Vancouver classification of renal neoplasia[J]. Am J Surg Pathol, 2013, 37(10): 1469-1489.
18	KURODA N, YAMASHITA M, KAKEHI Y, et al. Acquired cystic disease-associated renal cell carcinoma: an immunohistochemical and fluorescence in situ hybridization study[J]. Med Mol Morphol, 2011, 44(4): 228-232.
19	CHRABAŃSKA M, JAKUB R, BOGNA D. Bilateral and multifocal acquired cystic disease–associated renal cell carcinomas in patient with end-stage renal disease caused by systemic lupus erythematosus[J]. Int J Surg Pathol, 2021, 29(2): 198-204.
20	KATABATHINA V S, GARG D, PRASAD S R, et al. Cystic renal neoplasms and renal neoplasms associated with cystic renal diseases in adults: cross-sectional imaging findings[J]. J Comput Assist Tomogr, 2012, 36(6): 659-668.
21	EDO H, SUYAMA Y, SUGIURA H, et al. Acquired cystic disease-associated renal cell carcinoma extending to the renal pelvis mimicking urothelial carcinoma on computed tomography (CT): two case reports[J]. Am J Case Rep, 2020, 21: e926630.
22	BERKENBLIT R, RICCI Z, KANMANIRAJA D, et al. CT features of acquired cystic kidney disease-associated renal cell carcinoma[J]. Clin Imaging, 2022, 83: 83-86.
23	KITAJIMA K, YAMAMOTO S, KAWANAKA Y, et al. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison ¹¹C-choline and FDG PET/CT with dynamic contrast-enhanced CT[J]. Jpn J Radiol, 2019, 37(2): 165-177.
24	AKITA H, JINZAKI M, AKITA A, et al. Renal cell carcinoma in patients with acquired cystic disease of the kidney: assessment using a combination of T2-weighted, diffusion-weighted, and chemical-shift MRI without the use of contrast material[J]. J Magn Reson Imaging, 2014, 39(4): 924-930.
25	KIM S Y, WOO S, HWANG S I, et al. Usefulness of resistive index on spectral Doppler ultrasonography in the detection of renal cell carcinoma in patients with end-stage renal disease[J]. Ultrasonography, 2014, 33(2): 136-142.
26	LEE S H, PARK J S, KIM H, et al. Glycolysis on F-18 FDG PET/CT is superior to amino acid metabolism on C-11 methionine PET/CT in identifying advanced renal cell carcinoma at staging[J]. Cancers (Basel), 2021, 13(10): 2381.
27	CIMADAMORE A, CHENG L, SCARPELLI M, et al. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review[J]. Transl Androl Urol, 2021, 10(3): 1506-1520.
28	ROBILA V, KRAFT A O, SMITH S C. New entities, new technologies, new findings: a review of the cytologic features of recently established subtypes of renal cell carcinoma[J]. Cancer Cytopathol, 2019, 127(2): 79-97.
29	KURODA N, NARODA T, TAMURA M, et al. Acquired cystic disease-associated renal cell carcinoma: a clinicopathological study of seven cases[J]. Pol J Pathol, 2017, 68(4): 306-311.
30	BUTUROVIĆ-PONIKVAR J, VISNAR-PEROVIC A. Ultrasonography in chronic renal failure[J]. Eur J Radiol, 2003, 46(2): 115-122.
31	MEOLA M, PETRUCCI I. Ultrasound and color Doppler applications in chronic kidney disease[J]. G Ital Nefrol, 2012, 29(6): 699-715.
32	SIDHU P S, CANTISANI V, DIETRICH C F, et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (long version)[J]. Ultraschall Med, 2018, 39(2): e2-e44.
33	LIAKOPOULOS V, ELEFTHERIADIS T, MERTENS P R. Screening for renal cell carcinoma in dialysis patients[J]. Kidney Int, 2018, 94(6): 1238.
34	DAHLE D O, SKAUBY M, LANGBERG C W, et al. Renal cell carcinoma and kidney transplantation: a narrative review[J]. Transplantation, 2022, 106(1): e52-e63.

[1]	CHEN Siyuan, SHI Qing, FU Di, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili. Clinicopathologic characteristics, gene mutation profile, and prognostic analysis of diffuse large B-cell lymphoma with lung involvement [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1214-1220.
[2]	YAN Zhi, WU Xingyue, YAO Weiqin, YAN Lingzhi, JIN Song, SHANG Jingjing, SHI Xiaolan, WU Depei, FU Chengcheng. Dynamic changes and prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(7): 807-814.
[3]	CHEN Zixuan, LIU Min. Research progress on immune cell therapy in renal cell carcinoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(7): 916-925.
[4]	XU Tianyun, SHEN Yiming, JIANG Meng. Clinical management of heart failure with improved ejection fraction: treatment and maintenance [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(4): 493-499.
[5]	WANG Boen, CHEN Siyuan, SHI Qing, ZHANG Muchen, YI Hongmei, DONG Lei, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili. Clinicopathologic characteristics of patients with kidney-involved diffuse large B-cell lymphoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(9): 1162-1168.
[6]	SONG Chenlu, XIANG Jun, YANG Huizhong. Early alarming effect of serum heparin-binding protein on prognosis and occurrence of sepsis in severely burned patients [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(4): 474-481.
[7]	WANG Guijie, DU Chuanchong, LU Ye, ZHAO Jian, SHEN Xie, JIN Donglin, GENG Jiacai. Changes of serum high mobility group box 1 and soluble triggering receptor expressed on myeloid cells-1 in patients with multiple injuries and their prognostic significance [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 350-357.
[8]	CHEN Zixuan, LIU Min. Progress in mechanisms and treatment of sunitinib resistance in renal cell carcinoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(10): 1307-1315.
[9]	LUO Mengxing, ZOU Xin, GAO Yaxian, WU Xiaocui, YU Fangyou, HU Yang, ZENG Qibing, LIU Zhonghua. Analysis of the effect of anti-tuberculosis treatment and lung injury in patients with tuberculosis combined with underlying disease [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(8): 1017-1023.
[10]	LI Ying, TAN Yangxia, YIN Hongxin, JIANG Yanling, CHEN Li, MENG Guoyu. Research progress in the pathogenesis and prognosis of ZNF384 fusion subtype acute leukemia [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 631-640.
[11]	MEN Ru, ZHU Minxia, ZHANG Weiming. Serum potassium level in maintenance hemodialysis patients and its effect on outcome [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(4): 507-513.
[12]	WANG Anjun, LIU Ningning. Efficacy of radiotherapy in patients with rectal cancer undergoing chemotherapy and surgery: a retrospective study based on the SEER database [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(3): 320-332.
[13]	LI Fang, LI Kaiyang, WANG Jue, YAN Ruiyang, SHEN Hui, LIU Min. Expression and clinical significance of PLA2G2A in kidney renal papillary cell carcinoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 152-161.
[14]	HOU Shumin, SHAO Jingbo. Research progress in clinical characteristics, diagnosis and prognosis of TdT-negative lymphoblastic lymphoma/acute lymphoblastic leukemia [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(1): 120-124.
[15]	QIU Jiahui, CAI Qianqian, YANG Yan, CHENG Feichi, QIU Zhengjun, HUANG Chen. Value of combined perineural lymphovascular invasion and tumor-stroma ratio in guiding the prognosis of colorecatal cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(8): 1070-1080.